We use cookies for a better user experience. Read our Privacy Policy
I Agree
Lyme Disease Diagnostics Market
Lyme disease is the most prevalent vector-borne disease across the world. It is caused by the bacterium Borrelia burgdorferi and sometimes, Borrelia mayonii. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Lyme disease diagnostics measure Borrelia immunizers in the blood, or the cerebrospinal fluid (CSF) to identify the signs and symptoms of central nervous system disease. The surge in the frequency and prevalence of Lyme disease and rising investments from government organizations and large corporates for developing diagnostic kits are primary reasons contributing to the growth of the global Lyme disease diagnostics market.
Healthcare organizations such as CDC suggests two methods to identify these immunizers or antibodies to confirm a diagnosis of Lyme disease. The first diagnosis use practices such as an enzyme immunoassay (EIA) or immunofluorescence (IFA) method to measure Borrelia IgM and/or IgG antibodies. This diagnosis is intended to be very sensitive so that it will detect as many cases of Lyme disease as possible. The results may be positive even with similar types of bacteria such as the different tick-borne disease or syphilis or in other conditions, such as Lupus. The second diagnosis is recommended after the test of initial diagnosis with positive or indeterminate results. It is called a Western Blot that detects specific antibodies to multiple antigens to confirm the findings.
Lyme disease cases are presently crossing the 400,000 mark every year in U.S. alone, and the need for diagnosis of these patients is rapidly increasing, thus proving propitious for the global Lyme disease diagnostics market.
Request a sample to get extensive insights into the Lyme Disease Diagnostics Market
The worldwide COVID-19 pandemic has eclipsed the attention of healthcare professionals, affecting all areas of health and diagnostics care. The crisis has had several indirect health effects as well. The concern among individuals for the infection has decreased outpatient visits with healthcare providers. Symptomatic patients may be considered to have COVID-19 until negative test results are received, implying that evaluations for other diseases will be delayed, potentially leading to adverse outcomes. People with Lyme disease symptoms were asked to postpone their tests, as the coronavirus spread began to take over the world. People were recommended to be in quarantine as evaluation for other causes of the patient’s symptoms other than the COVID-19 virus was often deferred, risking delayed diagnosis and complications. Moreover, as Lyme and COVID-19 virus often start with non-specific flu-like symptoms with fever, headache, and general achiness and fatigue, it made patients and medical experts more concerned about both infections in individuals. Thus, patients were suggested to diagnose with the available medical institutions helping to diagnose other diseases.
The impact of this dramatic change in healthcare provision is only opening to be recognized, but includes decreased ambulatory visits with outpatient providers, hampering the growth of the global Lyme disease diagnostics market. In addition, the COVID-19 crisis has led to the adoption of telemedicine for the delivery of healthcare in many developed regions including North America and Europe. However, the impact of telemedicine on the diagnosis of acute infectious diseases such as Lyme disease is still under observation. Furthermore, misdiagnosis and delays in diagnosis of Lyme disease can potentially result in bacterial dissemination and involvement of distant organ systems, most importantly the neurologic, cardiac, and musculoskeletal systems. The neurologic association normally exhibits after the first few weeks of untreated virus and can result in meningitis, cranial nerve palsy, and radiculoneuritis. Post-COVID, however, there is likely to be a significant increase in the diagnosis of Lyme disease, as the number of vaccination is increasing, most people can feel safe to visit a diagnostics center. This is expected to propel the Lyme disease diagnostics market.
To understand how our report can bring difference to your business strategy, Ask for a brochure
The advancement in research and diagnosis of a new cytokine-based immunoassay for Lyme diagnosis can allow for earlier and more rapid diagnosis of the Lyme disease, if successful. Numerous researchers are working on the progress of a new, rapid point-of-care Lyme diagnostic test using lateral flow technologies. Metabolic biomarkers and biosignatures for enhanced diagnostics are being recognized and defined. All these studies are expected to contribute to new ways for identifying the Lyme disease, earlier-stage diagnosis, accurate staging of disease, or indications of successful treatment. This is anticipated to fuel the growth of the Lyme disease diagnostics market.
The advancements in the Lyme disease diagnostics portfolio by several major businesses have welcomed the approval by launching innovative Lyme disease diagnostics. T2 Biosystems developed a T2Lyme Panel diagnostic technique for the detection of Lyme disease-causing bacteria. Such innovations are likely to fuel the demand for upgraded Lyme disease diagnostics, thus driving the Lyme disease diagnostics market.
In the initial stages of diagnosis, researchers can now look at other molecules that arise earlier in infection instead of waiting for the antibodies creation in the blood. The experts are examining the pattern of a host of non-antibody molecules, or biomarkers that rise in response to B. burgdorferi infection, as compared to the pattern in other disease overlapping symptoms with Lyme disease. The pattern distinguishes early Lyme disease from the different illnesses examined, and could precisely diagnose the disease even in clinical samples that had tested negative by the current immunologic assay. In most cases, antibiotics are used to treat Lyme disease. It can help recover quickly and more completely the sooner the treatment begins.
Furthermore, North America holds the most number of major diagnostics centers and key market players. Rising healthcare expenditure, early availability of new products, and major patient base in the U.S. are expected to dominate the regional shares in the Lyme disease diagnostics market during the forecast period.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Lyme Disease Diagnostics Market
Analysts’ Viewpoint
The world has witnessed a rising number of Lyme disease cases in recent years, and expected to further grow with increasing worldwide population. People living in wooded areas are more likely to undergo Lyme disease tests. In addition, with the rising cases of tick-borne infectious diseases and increasing incidences of new types of vector-borne diseases, the demand for new diagnostics centers and improved diagnostics is gradually rising favoring the global Lyme disease diagnostics market. However, a lack of awareness about distinct infections and Lyme disease diagnostics in several developing economies is expected to hamper the market growth to some extent. Nevertheless, rising healthcare investments in such regions and increasing health consciousness among people are most likely to expand the global Lyme disease diagnostics market during the forecast period.
Lyme Disease Diagnostics Market – Segmentation
TMR’s study on the global Lyme disease diagnostic market includes information divided into four segments: diagnostic test, sample, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global Lyme disease diagnostic market are discussed in detail.
| Diagnostic Test |
|
| Sample |
|
| End User |
|
| Region |
|
Lyme disease diagnostics market to reach valuation of US$ 2.87 Bn by 2031
Lyme disease diagnostics market is projected to expand at a CAGR of 4% from 2021 to 2031
Lyme disease diagnostics market is driven by increase in incidence and rise in prevalence of Lyme disease, and surge in funding from government organizations and large corporates for developing Lyme disease diagnostic kits
North America dominated the global Lyme disease diagnostics market in 2020 and the trend is anticipated to continue during the forecast period
Key players operating in the global market include T2 Biosystems, Inc., QIAGEN, DiaSorin S.p.A, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Trinity Biotech plc, IGeneX Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Lyme Disease Diagnostics Market Forecast
4.5. Global Lyme Disease Diagnostics Market Outlook
5. Market Outlook
5.1. Lyme Disease Epidemiology
5.2. Regulations Related to Lyme Disease
5.3. COVID-19 Pandemic Impact on Lyme Disease Diagnostics Industry
5.4. Key Industry Development
6. Global Lyme Disease Diagnostics Market Analysis, by Diagnostic Test
6.1. Introduction
6.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test
6.3. Global Lyme Disease Diagnostics Market Forecast, by Diagnostic Test
6.3.1. Serological Test
6.3.1.1. ELISA
6.3.1.2. Western Blot
6.3.2. Polymerase Chain Reaction (PCR) Testing
6.3.3. Immunofluorescence (IFA)
6.3.4. lymphocyte Transformation Test
6.3.5. Urine Antigen Testing
6.3.6. Others
6.4. Global Lyme Disease Diagnostics Market Analysis, by Diagnostic Test
6.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
7. Global Lyme Disease Diagnostics Market Analysis, by Sample
7.1. Introduction
7.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by Sample
7.3. Global Lyme Disease Diagnostics Market Forecast, by Sample
7.3.1. Blood
7.3.2. Cerebrospinal Fluid (CSF)
7.3.3. Joint Fluid
7.3.4. Urine
7.4. Global Lyme Disease Diagnostics Market Analysis, by Sample
7.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
8. Global Lyme Disease Diagnostics Market Analysis, by End-user
8.1. Introduction
8.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by End-user
8.3. Global Lyme Disease Diagnostics Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Clinical Laboratories
8.3.3. Physician Clinics
8.3.4. Others
8.4. Global Lyme Disease Diagnostics Market Analysis, by End-user
8.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
9. Global Lyme Disease Diagnostics Market Analysis, by Region
9.1. Global Lyme Disease Diagnostics Market Scenario, by Region/Country
9.2. Global Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Region
9.3. Global Lyme Disease Diagnostics Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Lyme Disease Diagnostics Market Analysis
10.1. North America Lyme Disease Diagnostics Market Overview
10.2. North America Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
10.3. North America Lyme Disease Diagnostics Forecast, by Diagnostic Test
10.3.1. Serological Test
10.3.1.1. ELISA
10.3.1.2. Western Blot
10.3.2. Polymerase Chain Reaction (PCR) Testing
10.3.3. Immunofluorescence (IFA)
10.3.4. lymphocyte Transformation Test
10.3.5. Urine Antigen Testing
10.3.6. Others
10.4. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
10.5. North America Lyme Disease Diagnostics Market Analysis, by Sample
10.6. North America Lyme Disease Diagnostics Market Forecast, by Sample
10.6.1. Blood
10.6.2. Cerebrospinal Fluid (CSF)
10.6.3. Joint Fluid
10.6.4. Urine
10.6.5. Others
10.7. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
10.8. North America Lyme Disease Diagnostics Market Analysis, by End-user
10.9. North America Lyme Disease Diagnostics Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Clinical Laboratories
10.9.3. Physician Clinics
10.9.4. Others
10.10. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
10.11. North America Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country
10.12. North America Lyme Disease Diagnostics Market Forecast, by Country
10.12.1. U.S.
10.12.2. Canada
11. Europe Lyme Disease Diagnostics Market Analysis
11.1. Europe Lyme Disease Diagnostics Market Overview
11.2. Europe Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
11.3. Europe Lyme Disease Diagnostics Forecast, by Diagnostic Test
11.3.1. Serological Test
11.3.1.1. ELISA
11.3.1.2. Western Blot
11.3.2. Polymerase Chain Reaction (PCR) Testing
11.3.3. Immunofluorescence (IFA)
11.3.4. lymphocyte Transformation Test
11.3.5. Urine Antigen Testing
11.3.6. Others
11.4. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
11.5. Europe Lyme Disease Diagnostics Market Analysis, by Sample
11.6. Europe Lyme Disease Diagnostics Market Forecast, by Sample
11.6.1. Blood
11.6.2. Cerebrospinal Fluid (CSF)
11.6.3. Joint Fluid
11.6.4. Urine
11.7. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
11.8. Europe Lyme Disease Diagnostics Market Analysis, by End-user
11.9. Europe Lyme Disease Diagnostics Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Clinical Laboratories
11.9.3. Physician Clinics
11.9.4. Others
11.10. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
11.11. Europe Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.12. Europe Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
11.12.1. Germany
11.12.2. France
11.12.3. U.K.
11.12.4. Italy
11.12.5. Spain
11.12.6. Rest of Europe
12. Asia Pacific Lyme Disease Diagnostics Market Analysis
12.1. Asia Pacific Lyme Disease Diagnostics Market Overview
12.2. Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
12.3. Asia Pacific Lyme Disease Diagnostics Forecast, by Diagnostic Test
12.3.1. Serological Test
12.3.1.1. ELISA
12.3.1.2. Western Blot
12.3.2. Polymerase Chain Reaction (PCR) Testing
12.3.3. Immunofluorescence (IFA)
12.3.4. lymphocyte Transformation Test
12.3.5. Urine Antigen Testing
12.3.6. Others
12.4. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
12.5. Asia Pacific Lyme Disease Diagnostics Market Analysis, by Sample
12.6. Asia Pacific Lyme Disease Diagnostics Market Forecast, by Sample
12.6.1. Blood
12.6.2. Cerebrospinal Fluid (CSF)
12.6.3. Joint Fluid
12.6.4. Urine
12.7. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
12.8. Asia Pacific Lyme Disease Diagnostics Market Analysis, by End-user
12.9. Asia Pacific Lyme Disease Diagnostics Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Clinical Laboratories
12.9.3. Physician Clinics
12.9.4. Others
12.10. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
12.11. Asia Pacific Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.12. Asia Pacific Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
12.12.1. Japan
12.12.2. China
12.12.3. India
12.12.4. Australia & New Zealand
12.12.5. Rest of Asia Pacific
13. Latin America Lyme Disease Diagnostics Market Analysis
13.1. Latin America Lyme Disease Diagnostics Market Overview
13.2. Latin America Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
13.3. Latin America Lyme Disease Diagnostics Forecast, by Diagnostic Test
13.3.1. Serological Test
13.3.1.1. Elisa
13.3.1.2. Western Blot
13.3.2. Polymerase Chain Reaction (PCR) Testing
13.3.3. Immunofluorescence (IFA)
13.3.4. lymphocyte Transformation Test
13.3.5. Urine Antigen Testing
13.3.6. Others
13.4. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
13.5. Latin America Lyme Disease Diagnostics Market Analysis, by Sample
13.6. Latin America Lyme Disease Diagnostics Market Forecast, by Sample
13.6.1. Blood
13.6.2. Cerebrospinal Fluid (CSF)
13.6.3. Joint Fluid
13.6.4. Urine
13.7. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
13.8. Latin America Lyme Disease Diagnostics Market Analysis, by End-user
13.9. Latin America Lyme Disease Diagnostics Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Clinical Laboratories
13.9.3. Physician Clinics
13.9.4. Others
13.10. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
13.11. Latin America Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.12. Latin America Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
13.12.1. Brazil
13.12.2. Mexico
13.12.3. Rest of Latin America
14. Middle East & Africa Lyme Disease Diagnostics Market Analysis
14.1. Middle East & Africa Lyme Disease Diagnostics Market Overview
14.2. Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
14.3. Middle East & Africa Lyme Disease Diagnostics Forecast, by Diagnostic Test
14.3.1. Serological Test
14.3.1.1. ELISA
14.3.1.2. Western Blot
14.3.2. Polymerase Chain Reaction (PCR) Testing
14.3.3. Immunofluorescence (IFA)
14.3.4. lymphocyte Transformation Test
14.3.5. Urine Antigen Testing
14.3.6. Others
14.4. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
14.5. Middle East & Africa Lyme Disease Diagnostics Market Analysis, by Sample
14.6. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by Sample
14.6.1. Blood
14.6.2. Cerebrospinal Fluid (CSF)
14.6.3. Joint Fluid
14.6.4. Urine
14.7. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
14.8. Middle East & Africa Lyme Disease Diagnostics Market Analysis, by End-user
14.9. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Clinical Laboratories
14.9.3. Physician Clinics
14.9.4. Others
14.10. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
14.11. Middle East & Africa Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.12. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
14.12.1. GCC Countries
14.12.2. South Africa
14.12.3. Rest of Middle East & Africa
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. T2 Biosystems, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. QIAGEN
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. DiaSorin S.p.A.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Bio-Rad Laboratories
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. Thermo Fisher Scientific, Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Trinity Biotech plc
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Strategic Overview
15.2.7. IGeneX, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. Lyme Diagnostics Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. PerkinElmer, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
15.2.10. Oxford Immunotec plc (Boulder Diagnostics)
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. SWOT Analysis
15.2.10.4. Strategic Overview
15.2.11. Cenogenics Corporation
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Product Portfolio
15.2.11.3. SWOT Analysis
15.2.11.4. Strategic Overview
15.2.12. Quest Diagnostics
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Product Portfolio
15.2.12.3. SWOT Analysis
15.2.12.4. Strategic Overview
15.2.13. Ceres Nanosciences, Inc.
15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.13.2. Product Portfolio
15.2.13.3. SWOT Analysis
15.2.13.4. Strategic Overview
15.2.14. Galaxy Diagnostics
15.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.14.2. Product Portfolio
15.2.14.3. SWOT Analysis
15.2.14.4. Strategic Overview
List of Tables
Table 01: Global Lyme Disease Diagnostics Market
Table 02: 2019A Total Revenue
Table 03: 2031F Total Revenue
Table 04: Executive Summary
Table 05: Market Overview
Table 06: Key Industry Events
Table 07: Impact of COVID-19 Pandemic
Table 08: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 09: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031
Table 10: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031
Table 11: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Region , 2017–2031
Table 13: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 14: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031
Table 15: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031
Table 16: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 18: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 19: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2018
Table 20: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031
Table 21: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-segment, 2017–2031
Table 23: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 24: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031
Table 25: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031
Table 26: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 27: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-segment, 2017–2031
Table 28: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 29: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031
Table 30: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031
Table 31: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 32: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 33: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 34: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031
Table 35: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031
Table 36: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 37: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-segment, 2017–2031
Table 38: T2 Biosystems, Inc.: Business Overview
Table 39: T2 Biosystems, Inc.: Strategic Overview
Table 40: QIAGEN.: Business Overview
Table 41: QIAGEN.: Strategic Overview
Table 42: DiaSorin S.p.A.: Business Overview
Table 43: DiaSorin S.p.A.: Strategic Overview
Table 44: Bio-Rad Laboratories: Business Overview
Table 45: Bio-Rad Laboratories: Strategic Overview
Table 46: Thermo Fisher Scientific, Inc.: Business Overview
Table 47: Thermo Fisher Scientific, Inc.: Strategic Overview
Table 48: Trinity Biotech plc: Business Overview
Table 49: Trinity Biotech plc: Strategic Overview
Table 50: Trinity Biotech plc: Business Overview
Table 51: Trinity Biotech plc: Strategic Overview
Table 52: IGeneX, Inc.: Business Overview
Table 53: IGeneX, Inc.: Strategic Overview
Table 54: Lyme Diagnostics Ltd.: Business Overview
Table 55: Lyme Diagnostics Ltd.: Strategic Overview
Table 56: PerkinElmer, Inc.: Business Overview
Table 57: PerkinElmer, Inc.: Strategic Overview
Table 58: Oxford Immunotec plc (Boulder Diagnostics): Business Overview
Table 59: Oxford Immunotec plc (Boulder Diagnostics): Strategic Overview
Table 60: Cenogenics Corporation: Business Overview
Table 61: Cenogenics Corporation: Strategic Overview
Table 62: Quest Diagnostics.: Business Overview
Table 63: Quest Diagnostics.: Strategic Overview
Table 64: Ceres Nanosciences, Inc.: Business Overview
Table 65: Ceres Nanosciences, Inc.: Strategic Overview
Table 66: Galaxy Diagnostics: Business Overview
Table 67: Galaxy Diagnostics: Strategic Overview
List of Figures
Figure 01: % CAGR (2021–2031)
Figure 02: Drivers
Figure 03: Global Lyme Disease Diagnostics Market - Drivers (1)
Figure 04: Global Lyme Disease Diagnostics Market - Drivers (2)
Figure 05: Restraints
Figure 06: Opportunities
Figure 07: Lyme Disease Epidemiology
Figure 08: COVID-19 Pandemics Short- / Mid- / Long-term Impact on Lyme Disease Diagnostics Market
Figure 09: Introduction-Global Lyme Disease Diagnostics Market, by Diagnostic Test
Figure 11: Global Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2019 and 2031
Figure 12: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Serological Test, 2017–2031
Figure 13: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Polymerase Chain Reaction (PCR) Testing, 2017–2031
Figure 14: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Immunofluorescence (IFA), 2017–2031
Figure 15: Global Lyme Disease Diagnostics Market Value (US$ Mn), by lymphocyte Transformation Test, 2017–2031
Figure 16: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Urine Antigen Testing, 2017–2031
Figure 17: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Others, 2017–2031
Figure 18: Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2021–2031
Figure 19: Introduction - Global Lyme Disease Diagnostics Market Analysis, by Sample (1/4)
Figure 20: Introduction - Global Lyme Disease Diagnostics Market Analysis, by Sample (2/4)
Figure 21: Introduction - Global Lyme Disease Diagnostics Market Analysis, by Sample (3/4)
Figure 22: Introduction - Global Lyme Disease Diagnostics Market Analysis, by Sample (4/4)
Figure 23: Global Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2019 and 2031
Figure 24: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Blood, 2017–2031
Figure 25: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Cerebrospinal Fluid (CSF), 2017–2031
Figure 26: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Joint Fluid, 2017–2031
Figure 27: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Urine, 2017–2031
Figure 28: Introduction-Global Lyme Disease Diagnostics Market Analysis, by End-user (1/4)
Figure 29: Introduction-Global Lyme Disease Diagnostics Market Analysis, by End-user (2/4)
Figure 30: Introduction -Global Lyme Disease Diagnostics Market Analysis, by End-user (3/4)
Figure 31: Introduction -Global Lyme Disease Diagnostics Market Analysis, by End-user (4/4)
Figure 32: Global Lyme Disease Diagnostics Market Value Share Analysis, by End-user, 2019 and 2031
Figure 33: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 34: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Clinical Laboratories, 2017–2031
Figure 35: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Physician Clinics, 2017–2031
Figure 36: Global Lyme Disease Diagnostics Market Value (US$ Mn), by Others, 2017–2031
Figure 37: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: North America Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2019 and 2031
Figure 39: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2021–2031
Figure 40: North America Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2019 and 2031
Figure 41: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2020
Figure 42: North America Lyme Disease Diagnostics Market Value Share Analysis, by End-user, 2020
Figure 43: North America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2020
Figure 44: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 45: Europe Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2019 and 2031
Figure 46: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2021–2031
Figure 47: Europe Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2019 and 2031
Figure 48: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2020
Figure 49: Europe Lyme Disease Diagnostics Market Value Share Analysis, by End-user, 2020
Figure 50: Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2020
Figure 51: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 52: Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2019 and 2031
Figure 53: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2021–2031
Figure 54: Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2019 and 2031
Figure 55: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2020
Figure 56: Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, by End-user, 2020
Figure 57: Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2020
Figure 58: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 59: Latin America Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2019 and 2031
Figure 60: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2021–2031
Figure 61: Latin America Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2019 and 2031
Figure 62: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2020
Figure 63: Latin America Lyme Disease Diagnostics Market Value Share Analysis, by End-user, 2020
Figure 64: Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user, 2020
Figure 65: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 66: Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test, 2019 and 2031
Figure 67: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2021–2031
Figure 68: Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, by Sample, 2019 and 2031
Figure 69: Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample, 2020
Figure 70: Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, by End-user, 2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes